Validation of CD271 as a Therapeutic Target of Squamous Cell Carcinoma

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K14414
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Tumor therapeutics
• Research Institution: Miyagi Prefectural Hospital Organization Miyagi Cancer Center
• Principal Investigator: TANAKA NOBUYUKI 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 部長 (60280872)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: がん

Outline of Final Research Achievements

In order to validate a potential of CD271 as a squamous cell carcinoma target, CD271 was knock-downed by shRNA. CD271 inhibition inhibited both cell proliferation and migration. p42/44Erk inhibition as well as RhoA inhibition inhibited malignant phenotypes of HPCM2 cells. On the other hand, an anti-CD271 Ab did not show significant in vitro effect on the same cells. Together, CD271 is shown to be a potential target for squamous cell carcinoma therapy.

Free Research Field

腫瘍治療学